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There is increasing amount of information about the role of gut microbiome composition in 
communicable –or infectious diseases– and antibiotic resistance, but also how the human 
microbiota can be involved in chronic non-communicable diseases (NCDs) like diabetes and 
diabetes-related endophenotypes.(1) While much interest has recently been awakened that 
perturbations in gut microbiota are associated with the burden of antibiotic resistance(2), 
recent efforts investigating the potential causal effects or predictive value of information on 
the composition of microbiota, or their metabolites (e.g., Trimethylamine N-oxide (TMAO) in 
the circulation) or their functions (like changes in the gut-blood barrier (GBB) permeability) 
will open new avenues of research.(3-5)  
Recently, experimental studies demonstrated how administration of Akkermansia 
muciniphila, one of the most abundant members of the human gut microbiota, to mice can 
prevent the development of obesity and associated complications.(3) In other words, 
pasteurization of A. muciniphila enhances its capacity to reduce insulin resistance and 
dyslipidemia in mice.(3) These findings were in line with previous evidence that microbiota 
transfer from adult male to female mice yielded in protection against diabetes development.(6) 
Moreover, there is evidence in human adults how taking metformin can influence the several 
microbial populations such as an increase in A.muciniphila.(7) As such evidence in human 
studies provides valuable insights into our understanding of metabolic disorders, it is time to 
re-think about the underlying host gene-environment and host-microbiome interactions to 
explore missing players and predictors for the prevention and treatment of non-communicable 
diseases.  
So far, epidemiological observations or clinical trials have been mainly focused on 
genes, endophenotypes and the host gene- environment interactions.(8) Research studies in 
humans show that the host-microbiome communication is essential to maintain vital functions 
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of the healthy human over the life course.(1, 8) Therefore, the effect estimates (for human 
genes, biomarkers or interventions) obtained in the classical settings can be modified if one 
could take into account the transmission of human microbiota between people within a certain 
population.(1, 9, 10) Given the fact that microbiome traits are considered heritable and the 
trait associations tend to be small(8), complementary evidence from an integrative analysis of 
how the host gene-environment interaction can influence diversity and structure of the human 
microbiome and vice versa may find right matched pieces of the puzzle in these diseases.  
Another aspect of research for microbiome-disease associations is to investigate 
whether additional information on the composition and structure of the human microbiota is of 
value to improve the risk prediction for NCDs. In this context, the performance of prediction 
models including classical risk factors and the utility of microbiome traits needs to be formally 
quantified using prognostic metrics and clinical reclassification. (11, 12). Few out of several 
studies on microbiota metabolites or functions have conducted a formal quantification to 
support predictive utility of these phenotypes for NCDs.(4, 5)   
So, future lines of research need to focus on two hypotheses; human microbiota or a 
panel of microbiota-related phenotypes would improve risk prediction or be causally 
associated with NCDs. Such complementary strands of evidence may demonstrate if 
information about human microbiota can serve as prognostic markers for predicting clinical 
health outcomes and behavior; or as novel targets for new therapeutic and prevention 
strategies in clinical or public health practice.  
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